Novo Nordisk A/S - share repurchase programme
25 März 2024 - 12:58PM
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 25 March 2024 – On 6 February 2024,
Novo Nordisk initiated a share repurchase programme in accordance
with Article 5 of Regulation No 596/2014 of the European Parliament
and Council of 16 April 2014 (MAR) and the Commission Delegated
Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour
Rules"). This programme is part of the overall share repurchase
programme of up to DKK 20 billion to be executed during a 12-month
period beginning 6 February 2023.
Under the programme initiated 6 February 2024, Novo Nordisk will
repurchase B shares for an amount up to DKK 2.1 billion in the
period from 6 February 2024 to 30 April 2024.
Since the announcement 18 March 2024, the following transactions
have been made:
|
|
Number of B shares |
Average purchase price |
Transaction value,
DKK |
|
Accumulated, last announcement |
1,230,000 |
|
1,052,551,945 |
| 18 March
2024 |
40,000 |
904.75 |
36,189,858 |
| 19 March
2024 |
40,000 |
909.40 |
36,376,082 |
| 20 March
2024 |
39,500 |
899.76 |
35,540,413 |
| 21 March
2024 |
40,000 |
884.84 |
35,393,711 |
|
22 March 2024 |
40,000 |
891.31 |
35,652,591 |
|
Accumulated under the programme |
1,429,500 |
|
1,231,704,601 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
47,970,207 B shares of DKK 0.10 as treasury shares, corresponding
to 1.1% of the share capital. The total amount of A and B shares in
the company is 4,510,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 20 billion during a 12-month period beginning 6 February 2024.
As of 22 March 2024, Novo Nordisk has since 6 February 2024
repurchased a total of 1,429,500 B shares at an average share price
of DKK 861.63 per B share equal to a transaction value of DKK
1,231,704,601.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contact for further information.
| Media: |
|
| Ambre
James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz
Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
|
|
Investors: |
|
| Daniel Muusmann
Bohsen +45 3075 2175 dabo@novonordisk.com |
Jacob Martin
Wiborg Rode +45 3075 5956 jrde@novonordisk.com
|
| David Heiberg
Landsted +45 3077 6915 dhel@novonordisk.com |
Mark Joseph
Root (US) +1 848 213 3219 mjhr@novonordisk.com |
| Sina Meyer
+45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com
|
- 20240325 Safe Harbour CA
- 20240325 safe harbour transaction details
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
